Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Natalizumab (Tysabri).

Selewski DT, Shah GV, Segal BM, Rajdev PA, Mukherji SK.

AJNR Am J Neuroradiol. 2010 Oct;31(9):1588-90. doi: 10.3174/ajnr.A2226. Epub 2010 Aug 5. Review.

2.

Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.

Rudick RA, Sandrock A.

Expert Rev Neurother. 2004 Jul;4(4):571-80. Review.

PMID:
15853576
3.

Natalizumab treatment reduces endothelial activity in MS patients.

Millonig A, Hegen H, Di Pauli F, Ehling R, Gneiss C, Hoelzl M, Künz B, Lutterotti A, Rudzki D, Berger T, Reindl M, Deisenhammer F.

J Neuroimmunol. 2010 Oct 8;227(1-2):190-4. doi: 10.1016/j.jneuroim.2010.07.012. Epub 2010 Aug 23.

PMID:
20739072
4.

Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale.

Rice GP, Hartung HP, Calabresi PA.

Neurology. 2005 Apr 26;64(8):1336-42. Review.

PMID:
15851719
5.

Natalizumab: targeting alpha4-integrins in multiple sclerosis.

Engelhardt B, Kappos L.

Neurodegener Dis. 2008;5(1):16-22. Review.

PMID:
18075270
6.

Natalizumab (Tysabri) for relapsing multiple sclerosis.

[No authors listed]

Med Lett Drugs Ther. 2005 Feb 14;47(1202):13-5.

PMID:
15711498
7.

[Blocking adhesion molecules with natalizumab in multiple sclerosis].

Schreiner B, Kieseier BC, Hartung HP, Hohlfeld R, Wiendl H.

Nervenarzt. 2005 Aug;76(8):999-1005. Review. German.

PMID:
15812675
8.

Natalizumab (Tysabri) treatment for relapsing multiple sclerosis.

Johnson KP.

Neurologist. 2007 Jul;13(4):182-7. Review.

PMID:
17622909
9.

[Natalizumab (Tysabri)].

Ravnborg M.

Ugeskr Laeger. 2007 Sep 17;169(38):3184-7. Danish.

PMID:
17910826
10.

Natalizumab for multiple sclerosis?

[No authors listed]

Drug Ther Bull. 2008 Sep;46(9):69-72. doi: 10.1136/dtb.2008.09.0021. Review.

PMID:
18784381
11.

Monoclonal antibodies in MS: mechanisms of action.

Bielekova B, Becker BL.

Neurology. 2010 Jan 5;74 Suppl 1:S31-40. doi: 10.1212/WNL.0b013e3181c97ed3. Review.

PMID:
20038761
12.

The effects of natalizumab on the innate and adaptive immune system in the central nervous system.

Stüve O.

J Neurol Sci. 2008 Nov 15;274(1-2):39-41. doi: 10.1016/j.jns.2008.03.022. Epub 2008 May 12. Review.

PMID:
18474372
13.

Multiple sclerosis and Natalizumab.

Fiore D.

Am J Ther. 2007 Nov-Dec;14(6):555-60.

PMID:
18090880
14.
15.

Natalizumab: new drug. Multiple sclerosis: risky market approval.

[No authors listed]

Prescrire Int. 2008 Feb;17(93):7-10.

PMID:
18354844
16.

The role of natalizumab in the treatment of multiple sclerosis.

Coyle PK.

Am J Manag Care. 2010 Jun;16(6 Suppl):S164-70. Review.

17.

Natalizumab and the role of alpha 4-integrin antagonism in the treatment of multiple sclerosis.

O'Connor P.

Expert Opin Biol Ther. 2007 Jan;7(1):123-36. Review.

PMID:
17150024
18.

[Natalizumab in multiple sclerosis: the second treatment revolution].

Tourbah A.

Presse Med. 2008 Jan;37(1 Pt 2):81-4. Epub 2007 Nov 26. Review. French.

PMID:
18031976
19.

Natalizumab: AN 100226, anti-4alpha integrin monoclonal antibody.

[No authors listed]

Drugs R D. 2004;5(2):102-7. Review.

PMID:
15293871
20.
Items per page

Supplemental Content

Write to the Help Desk